BIT Group opens 2nd Shenzhen unit; India's NPPA caps prices on 18 drugs;

> Germany-based medical device CMO BIT Group has opened a second Chinese manufacturing facility in Shenzhen in a joint venture with EDAN Instruments based in Shenzhen and that has a focus in medical monitoring technology. Release

> India's National Pharmaceutical Pricing Authority has capped prices of 18 drug formulations, including treatments for diabetes, hypertension and pneumonia, NDTV reported, citing a statement. India sets a formula for essential drug prices that uses a simple average of all medicines in a particular therapeutic segment that have more than 1% of the market. Report

> Japan's Takeda Pharmaceutical saw first-half profit drop 11.5% to Y54.4 billion ($450 million) and sales up 6.2% as CEO Christophe Weber said that the company is "getting closer to underlying revenue growth." Weber took over the top job in April. The company said it sees full-year revenue growth in the low-single digits. Release

> Johnson & Johnson ($JNJ) China subsidiary Xi'an Janssen will launch 10 drug products in the next 5 years, China Daily reported, citing executives who laid out four treatment areas covering tumors, autoimmune system ailments and mental health and infectious and metabolic diseases such as hepatitis and diabetes. Report

> Japan's Eisai presented Phase III results of an Asia-based trial to treat partial-onset seizures using antiepileptic candidate perampanel as an adjunct therapy that showed a significantly higher reduction in seizure frequency compared to placebo. The presentation was made at the 49th Congress of the Japan Epilepsy Society held Oct. 30 and 31. Release

> Japan's Eisai and San Diego-based Arena Pharmaceuticals ($ARNA) will present a series of lorcaserin HCl (Belviq) data at the Obesity Society and the American Society for Metabolic and Bariatric Surgery this week in Los Angeles. Release

> Japan's Shionogi & Co. could make a Japan release of what it billed as the first one-day treatment for flu as early as 2018, the Nikkei Asian Review reports, adding the oral treatment inhibits enzymes that aid the spread of viruses that enter the body through the throat or nose. Report

> China FDA said the APEC (Asia-Pacific Economic Cooperation) Health Sciences Research Institute was opened this week at Peking University Institute of Health Sciences and will focus on regional health policy research. Release

> China-based Tianjin CanSino Biotechnology broke ground on its vaccine manufacturing plant in Tianjin and marked the occasion by noting its recent fund raising from Qiming Venture Partners, Lilly Asia Ventures and other investors. The company has raised $30 million in venture capital dedicated to its vaccine efforts, according to a press release, building on $10 million pledged two years earlier from Lilly as lead investor. Release